Hugh Cole - Feb 1, 2022 Form 4/A - Amendment Insider Report for Jounce Therapeutics, Inc. (JNCE)

Role
Chief Business Officer
Signature
/s/ Caroline Gammill, Attorney-in-fact
Stock symbol
JNCE
Transactions as of
Feb 1, 2022
Transactions value $
$0
Form type
4/A - Amendment
Date filed
3/17/2022, 08:50 PM
Date Of Original Report
Feb 3, 2022
Previous filing
Jan 11, 2022
Next filing
Jun 21, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction JNCE Stock Option (Right to Buy) Award $0 +85K $0.00 85K Feb 1, 2022 Common Stock 85K $7.56 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Stock Option will vest (i) as to 55,000 shares of the Stock Option, quarterly in 16 equal installments following January 1, 2022 and (ii) as to 30,000 shares of the Stock Option, on January 1, 2023.

Remarks:

This Form 4/A amends the Form 4 filed on February 3, 2022 to correct the vesting schedule of the Stock Option granted to the Reporting Person.